Medicare Part B Payment Boost For Biosimilars A Positive Step But ‘More Must Be Done’

05 Oct 2022

The policy is welcomed by biosimilar stakeholders, but amounts to a relatively small increase. To qualify for the revised payment, a biosimilar must have an average sales price that is less than its reference drug’s ASP and not all do.

Will an incremental payment boost Improve biosimilar Uptake In Medicare? • Source: Shutterstock

Biosimilars may see better uptake in the Medicare Part B program over the next five years if prescribers are swayed by the prospect of higher reimbursement for the follow-ons versus their reference drugs.

The Centers for Medicare and Medicaid Services launched a temporary, five-year increase in Medicare Part B reimbursement for biosimilars from...